{
    "nctId": "NCT03519178",
    "briefTitle": "A Study of PF-06873600 in People With Cancer",
    "officialTitle": "PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 155,
    "primaryOutcomeMeasure": "Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer\n\n  \u2022 Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy\n* Have a diagnosis of metastatic triple negative breast cancer (TNBC)\n\n  \u2022 Up to 1-2 prior lines of chemotherapy\n* Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC)\n\n  \u2022 Up to 2-3 prior lines of therapy\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n* Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)\n* Measurable disease as defined by RECIST 1.1 is required (Part 1B and Part 2 only)\n\nExclusion Criteria:\n\n* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases\n* Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ\n* Major surgery or radiation within 4 weeks prior to study entry\n* Last anti-cancer treatment within 2 weeks prior to study entry\n* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry\n* Pregnant or breastfeeding female patients\n* Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}